Overview


According to FutureWise analysis the market for Antimicrobial Peptides in 2023 is US$ 5.62 billion, and is expected to reach US$ 8.97 billion by 2031 at a CAGR of 6.00%.

Antimicrobial peptides (AMPs) are short proteins produced by various organisms, including humans, animals, plants, and bacteria. They have broad-spectrum antimicrobial activity against bacteria, fungi, viruses, and parasites. Antimicrobial peptides (AMPs) are a fundamental element of the innate immune system, functioning as the body's initial barrier against infections.  AMPs have a variety of different mechanisms of action. Some AMPs disrupt the cell membrane of microbes, leading to cell death. Other 
AMPs interfere with microbial metabolism or protein synthesis. Still, others activate the host immune system to kill microbes. AMPs have several advantages over traditional antibiotics. They are effective against a wide range of microbes, including drug-resistant strains. They are also relatively non-toxic to human cells. Additionally, AMPs are less likely to induce microbial resistance than traditional antibiotics. 

AMPs are still in the early stages of development as therapeutic agents. However, they have the potential to revolutionize the way that we treat infections. AMPs are being investigated for a wide range of applications, including treating drug-resistant infections, preventing infections, and treating inflammatory diseases and cancer. Some examples of AMPs and their sources are Human AMPs: LL-37, defensins, cathelicidins; Animal AMPs: Magainins (frogs), melittin (bees), statins (salivary proteins); Plant AMPs: Thionins (barley), defensins (potatoes), cecropins (moth larvae); Bacterial AMPs: Nisin (Lactococcus lactis), subtilin (Bacillus subtilis).

FutureWise Market Research has published a report that provides an insightful analysis of Antimicrobial Peptides Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antimicrobial Peptides Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • AnaSpec
  • Hycult Biotech
  • Novabiotics
  • AMP Biotech
  • GenScript
  • Phoenix Biotech
  • Ruixing Biotechnology
  • Ontores
  • Chinese Peptide
  • Sunsmile
  • Zhongnong Yingtai Biotechnology
  • Glam Technology
  • ProteLight Pharmaceutical & Biotechnology

(Note: The list of the major players will be updated with the latest market scenario and trends)

Antimicrobial peptides possess a unique mode of action, targeting bacterial cell membranes or intracellular components, making them less likely to induce resistance. This critical advantage has enhanced substantial interest from the pharmaceutical and medical industries.
Furthermore, the surge in the prevalence of infectious diseases and the growing global population have created a pressing need for novel and effective antimicrobial agents. Antimicrobial peptides are versatile in targeting various pathogens, including bacteria, viruses, fungi, and even certain parasites. This versatility makes them attractive for therapeutic development against different infectious agents, driving the market. Moreover, advancements in biotechnology and peptide synthesis techniques have facilitated the production of antimicrobial peptides in large quantities and at lower costs. This has alleviated their widespread use in clinical applications, propelling the market growth.

However, Antimicrobial peptides can be sensitive to factors like pH, temperature, and salinity, which can affect their stability and efficacy and constrain the market. Another significant restraint is the potential for toxicity and immunogenicity. Some antimicrobial peptides, particularly those derived from natural sources, may exhibit cytotoxic effects on mammalian cells. Additionally, there is a risk of immune responses against specific peptides, potentially limiting their long-term use and restraining the market growth.

By Type

  • Plant Antimicrobial Peptides
  • Microbial Antimicrobial Peptides
  • Animal Antimicrobial Peptides

By End-User

  • Pharmaceuticals
  • Feed Additives
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.
By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to emerging healthcare settings. Asia-Pacific is expected to be the fastest growing in the forecast period due to the large patient pool, increased income levels, and expanding healthcare infrastructure. In addition, advanced research and development are occurring, enhancing the treatment modalities and interventions with more innovations in this region, driving the market.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antimicrobial Peptides Market By Type, By End-User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antimicrobial Peptides Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antimicrobial Peptides Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antimicrobial Peptides Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antimicrobial Peptides Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Plant Antimicrobial Peptides
        2. Microbial Antimicrobial Peptides
        3. Animal Antimicrobial Peptides

  • 8.   Global Antimicrobial Peptides Market, By End-User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceuticals
        2. Feed Additives
        3. Others

  • 9.   North America Antimicrobial Peptides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antimicrobial Peptides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antimicrobial Peptides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antimicrobial Peptides Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. AnaSpec
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Hycult Biotech
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novabiotics
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AMP Biotech
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. GenScript
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Phoenix Biotech
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ruixing Biotechnology
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Ontores
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Chinese Peptide
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Sunsmile
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Zhongnong Yingtai Biotechnology
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Glam Technology
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. ProteLight Pharmaceutical & Biotechnology
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients